Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding

Barinthus Biotherapeutics (BRNS) Short-Term Debt repayments (2022)

Barinthus Biotherapeutics (BRNS) has disclosed Short-Term Debt repayments for 1 consecutive years, with $159000.0 as the latest value for Q1 2022.

For Q1 2022, Short-Term Debt repayments changed N/A year-over-year to $159000.0; the TTM value through Dec 2022 reached $159000.0, changed N/A, while the annual FY2022 figure was $159000.0, N/A changed from the prior year.
Short-Term Debt repayments hit $159000.0 in Q1 2022 for Barinthus Biotherapeutics.
Across five years, Short-Term Debt repayments topped out at $159000.0 in Q1 2022 and bottomed at $159000.0 in Q1 2022.